Acceleron Pharma Inc (NASDAQ: XLRN) was a top gainer in yesterday’s trading session, and closed the day with gains of 50.16%. This followed the company’s announcement that, its mid-stage study for Sotatercept, its treatment candidate for people with PAH (Pulmonary Arterial Hypertension), was a success.
The phase 2 study is randomized and is a placebo-controlled trial aimed at testing the efficacy and safety of the treatment. The company announced that, the primary goal of the study is a change in pulmonary vascular resistance over 24-weeks. The company further announced that, the study involved 106 patients who were randomly selected to get 0.3mg/kg of the company’s treatment (Sotatercept) or 0.7 mg/kg of Sotatercept subcutaneously every 3 weeks, and combine it with other background PAH therapies in a period of 24-weeks.
The company announced that, the test patients showed a significant drop in PVR, which was the primary endpoint at the end of 24-weeks, as compared to the placebo. The company also announced that, the treatment met its secondary endpoint, that of 6MWD, WHO functional class, and amino-terminal brain natriuretic propeptide among others.
The company also announced that, the treatment was well tolerated. It stated that, 97 of the 106 patients are now going through an extended 18-month of further studies. It also stated that, results from these studies will be announced at a later date in the year. The company further announced that, Sotatercept was being taken through another phase 2 study on patients dealing with PAH.
Commenting on this progress, CEO Habib Dable stated that, the company was happy with the topline results from the trial. He added that, the data was encouraging, and it was an indicator that Sotatercept would be beneficial to patients.
From its price action, XLRN is in a breakout. The company opened the day at $78.74 and traded between a low of $73.51 and a high of $82 before closing the day at $79.39. Volumes in the day stood at 8.68 million.
About Acceleron Pharma Inc
Acceleron Pharma Inc is a biopharma company that develops treatments for rare diseases. It is based in Cambridge, Massachusetts.